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The aim of this study was to investigate the anti-inflammatory effects of parthenolide (PTN) in human 
renal mesangial cells (HRMCs) under high ambient glucose conditions. First we determined the non-
cytotoxic concentration of PTN in HRMCs by performing the MTS assay. Enzyme-linked immunosorbent 
(ELISA) analysis was performed to determine the expressions of interleukin (IL)-1, IL-18, tumor-
necrosis factor (TNF)-, transforming growth factor (TGF)-1, monocyte chemoattractant protein (MCP)-
1, macrophage inflammatory protein (MIP)-1, RANTES and prostaglandin (PG)E2. The total nitric oxide 
(NO) was determined by performing the Griess reaction. Treatment with less than 50 mol/L PTN 
concentration did not affect the viability of HRMCs, while more than 100 µmol/L concentrations 
markedly altered the cell viability. In the present study, treatment with 50 mmol/L glucose markedly 
increased the level of IL-1, IL-18, TNF-, TGF-1, MCP-1, MIP-1, RANTES, PGE2 and NO. PTN 
remarkably abolished the increase in the level of these molecules in a dose-dependent manner. 
Moreover, treatment with PTN concentration of 20 µmol/L almost completely reversed IL-1 and TNF- 
expression, and treatment with 50 µmol/L reversed the expression of RANTES. In conclusion, 
parthenolide can inhibit the high-glucose-induced expression of inflammatory cytokines in HRMCs. 
Hence, PTN may be considered a promising drug with potent anti-inflammatory effect in addition to its 
strong anticancer, anti-angiogenesis, and antineurodegenerative effects. 
 





The understanding of the pathogenesis of diabetes mellitus 
has changed in the last few years due to the pivotal roles 
of inflammatory pathways in the development and 
progression of diabetic nephropathy (DN) (Navarro and 
Mora, 2005). The dysfunction of mesangial cells is one of 
the key factors causing glomerular injury in DN. When 
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display growth abnormalities and increased expression 
and synthesis of cytokines, including transforming growth 
factor-1 (TGF-1) (Kanwar et al., 2008) and tumor 
necrosis factor- (TNF-) (Navarro and Mora, 2005; Naito 
et al., 2009). Moreover, several lines of evidence support 
the fact that many chemokines like CCL2/monocyte 
chemoattractant protein (MCP)-1, CCL3/macrophage 
inflammatory protein (MIP)-1, and CCL5/RANTES play 
an important role in the pathogenesis of DN or non-
diabetic nephropathy (NDN) (Teramoto et al., 2008; 
Campbell et al., 2006; Mezzano et al., 2004). Further, 
activated mesangial cells produce chemokines and play a 





matory events within the glomerulus. The release of 
chemokines by intrinsic renal cells may promote the influx 
of leukocytes into the injured tissue and contribute to the 
progression of inflammatory renal injury (Brown et al., 
1996).  
The progressive changes in the kidney of diabetic 
patients, such as mesangial matrix expansion and eventual 
glomerular sclerosis, result in a remarkable decrease in 
the glomerular filtration rate (GFR) until the advancement 
to end-stage renal disease (ESRD). Although,many 
therapeutic interventions delay the development or retard 
the progression of DN, no available intervention can stop 
or reverse the progression of this condition (Wang et al., 
2008). The revelation that DN is an inflammatory disease 
triggered by altered metabolic factors has opened new 
and important therapeutic perspectives. Many efforts 
were focused on identifying novel anti-inflammatory drugs 
that could block the inflammatory pathway at a very early 
stage of gene expression. In this regard, a natural 
compound, namely, parthenolide (PTN), which is a 
sesquiterpene lactone isolated from the extracts of 
Mexican-Indian medicinal herb (Tanacetum parthenium), 
has attracted considerable interest. PTN-containing herbs 
have been commonly used for the treatment of various 
inflammatory conditions such as migraine, arthritis, and 
asthma (López-Franco et al., 2006; Heinrich et al., 1998). 
Several groups have reported that PTN inhibits nuclear 
factor-kappa B (NF-B) activation in cultured cells and 
experimental models of diabetes (López-Franco et al., 
2006; Hehner et al., 1998). However, the effect of PTN 
on the synthesis of inflammatory factors in renal 
mesangial cells under hyperglycemic condition has not 
yet been investigated (López-Franco et al., 2006). 
In this study, we report that PTN treatment is beneficial 
to human renal mesangial cells (HRMCs) under hyper-
glycemic condition, which can be partially attributed to the 
inhibition of inflammatory factor expression. 
 
 




L-Glucose was obtained from Sigma Chemical Co., USA. HRMCs 
were purchased from ScienceCell, USA. PTN was obtained from 
Sigma, USA. PTN was dissolved in 100 mM dimethylsulfoxide 
(DMSO), stored at –30°C and diluted to prepare solutions of 10, 20, 
and 50 M final concentrations. The Cell Titer 96 aqueous cell 
viability assay kit was purchased from Promega, USA. All other 
chemicals were of reagent grade. Human IL-1, IL-18, TNF-, 
monocyte chemoattractant protein (MCP)-1, macrophage inflammatory 
protein (MIP)-1, RANTES, TGF-1, PGE2, enzyme-linked immu-
nosorbent assay (ELISA) kits, and NO assay kit were purchased 
from R&D systems, USA. 
 
 
Cell culture and treatment 
 
To make cells better response to high- glucose stimulate, HRMCs 
were cultured in low-glucose Dulbecco’s Modified Eagle Media 
(DMEM) medium supplemented with 10% heat-inactivated fetal 
bovine serum (Gibco, Grand Island, NY, USA), 5.6 mmol/L glucose, 




glutamine, and antibiotics (penicillin and streptomycin) and incubated 
at 37°C under 5% CO2 for 1 month, after which the following 





HRMCs (1 × 104 cells/well in 96-well plate) were treated with PTN 
(0, 1, 5, 10, 20, 50, 100, and 200µmol/L) for 24 h and cell viability 
was evaluated by MTS assay. The assay included tetrazolium 
compound MTS (3, 4-(5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt) and an electron 
coupling reagent phenazine methosulfate (PMS). MTS is reduced 
by viable cells to formazan, which can be estimated by measuring 
the absorbance at 490 nm using a spectrophotometer. Formazan 
production was time dependent and proportional to the number of 
viable cells. Cultures were seeded at 1 × 104 cells/well, and the 
cells were allowed to attach overnight. After incubation for the 
indicated time with the appropriate medium, 20 l MTS/PMS 
mixture was added to each well and the cells were incubated for 1 
h; finally, the absorbance was measured at 490 nm. Background 
absorbance of the control samples was subtracted. Three duplicate 
studies were performed for each experimental condition. 
 
 
Evaluation of cytokine production 
 
The inhibitory effect of PTN on IL-1, IL-18, TNF-, MCP-1, MIP-
1, RANTES, and TGF-1 production was determined using ELISA. 
HRMCs (3 × 105 cells/well in 6-well plate) were preincubated with or 
without PTN for 2 h and continuously incubated in 5.6 (normal 
glucose, NG) or 50 mmol/L glucose (high glucose, HG) for the next 
24 h. Subsequently, the supernatants were assayed for the levels 
of above mentioned cytokines using ELISA kits (R&D Systems, MN, 
USA) according to the manufacturer’s procedures. 
 
 
Assay for PGE2 production 
 
The inhibitory effects of PTN on PGE2 production in HG-treated 
HRMCs were analyzed by competitive ELISA according to the 
manufacturer’s procedures (R&D Systems, MN, USA). The lower 





HRMCs were preincubated with or without PTN for 2 h and then 
continuously activated in HG condition (50 mmol/L) for 24 h. NO 
levels were determined by performing the Griess reaction (R&D 
Systems, MN, USA). The absorbance of the product dye was 
measured at 540 nm using a flow-through spectrophotometer. The 





Student’s t-test and one-way analysis of variance (ANOVA) were 
used to determine the statistical significance of differences between 
the experimental and control groups. The P values of 0.05 or less 





Effect of PTN on the viability of HRMCs 
 
We evaluated the cytotoxic effect of PTN before performing  






Figure 1. Effect of PTN on the viability of HRMCs. HRMCs (1 × 104 cells / well in 96-well plate) were incubated with 
PTN of different concentrations for 24 h. Cell viability was determined by performing the MTS assay. Data represent 




Table 1. Groups in different culture conditions in this study. 
 
Condition/group 1 2 3 4 5 6 7 
Glucose (mmol/L) 5.6 50 50 50 50 50 50 




further studies. The viability of HRMC (Fax: +86-571-
87236582s) after incubation with different PTN prepa-
rations for 24 h was determined by MTS assay. As shown 
in Figure 1, the viability of HRMCs did not change 
remarkably when incubated with PTN concentrations of 
0–50µmol/L but the viability was markedly affected at 
concentrations above 100µmol/L. Therefore, PTN at less 
than 50 µmol/L concentration was suitable to exert 
selective pharmacological action without any interference 
with normal cell function.  
 
 
Inhibitory effect of PTN on HG-induced upregulation 
of inflammatory Factors production in HRMCs 
 
To assess the inhibitory effect of PTN on HG-mediated 
production of inflammatory factors, we evaluated the 
levels of IL-1, IL-18, TNF-, MCP-1, MIP-1, RANTES, 
TGF-1, PGE2 and NO production by performing ELISA. 
The samples were pretreated with PTN and then 
subjected to different glucose conditions. Cells were 
pretreated with various concentrations of PTN in the 5.6 
(NG) or 50 mmol/L (HG) glucose for 24 h (Table 1). The 
expression of inflammatory molecules in the supernatants 
of HG-treated HRMCs was remarkably upregulated as 
compared to that in NG-treated cells. Further, PTN 
treatment significantly decreased the HG-induced 
production of the above mentioned factors (Figures 2A–I), 
indicating that PTN may commonly affect HG-mediated pro-
inflammatory responses of HRMCs. Furthermore, the 
inhibitory effect was dose dependent. In fact, PTN almost 
completely reversed IL-1 and TNF- expression and NO 
production at 20 µmol/L (Figures 2B, C, E), PGE2 and 





DN is one of the main ‘‘microvascular’’ complications of 
diabetes (Kanwar et al., 2008). Activated innate immunity 
and inflammation are important factors involved in the 
pathogenesis of diabetes and convincing data is present 
to indicate that inflammatory responses are induced in 
type 2 diabetes (Crook, 2004; Pickup, 2004). The renal 
lesions in type 1 and 2 diabetes mellitus are similar 
(Kanwar et al., 2008). In 1991, Hasegawa et al. were the 
first to suggest that proinflammatory cytokines could 
participate in the development of DN (Hasegawa et al., 
1991). There was an urgent requirement of good 
therapeutic modalities to block the inflammatory pathway. 
Recent studies revealed that PTN can be used as an 
efficient anti-inflammatory compound for the treatment of 
autoimmune diseases and inflammatory diseases, including 
arthritis and asthma (Nam, 2006; Yao et al., 2007). The 
results of our study confirm the existing data and provide 
new data which suggests that under high ambient glucose 
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Figure 2. Inhibitory effect of PTN on HG-induced upregulation of inflammatory factors production. HRMCs (3 × 105/wells in 6-well plate) were 
preincubated with or without honokiol for 2 h, and then continuously incubated in 5.6 or 50 mmol/L glucose for 24 h. Levels of IL-1, IL-18, 
TNF-, MCP-1, MIP-1, RANTES, TGF-1, and PGE2, and NO production were determined by ELISA and Griess reaction, respectively. 
Data represent mean ± SEM (n = 3). P < 0.05, P < 0.01 vs 5.6 mmol/L glucose (group 1); *P < 0.05, **P < 0.01 vs 50 mmol/L glucose 




conditions human mesangial cells can induce the 
upregulation of the expression of several inflammatory 
factors and that PTN markedly suppressed the expression 
of inflammatory proteins activated in HG condition. 
We first treated HRMCs with variable PTN concentrations 
(0, 1, 5, 10, 20, 50, 100, and 200 mol/L) for 24 h, and 
subsequently evaluated the cytotoxicity of PTN by 
performing the MTS assay. The results indicated that as 
compared to the control sample more than 99% HRMCs 
were viable after 24 h of treatment with a range of PTN 
concentrations below 50mol/L. However, PTN concen-
trations above 100mol/L resulted in obvious cytotoxic 
effects on HRMCs (Figure. 1). Thus, we used 0, 1, 5, 10, 
20, and 50 mol/L of PTN for HRMC experiments; these 
PTN concentrations were non toxic and more than 99% 
cells were viable after 24 h incubation. The final concen-
tration of DMSO was same in the control and PTN-
containing samples. 
The direct harmful effect of TNF- on the glomerular 
protein permeability barrier is independent from its other 
effects such as modification of hemodynamic factors or 
recruitment of inflammatory cells. It is particularly relevant 
that TNF- is suggested to be a critical factor that 
contributes to sodium retention and renal hypertrophy, 
which are important renal alterations that occur during the 
initial stage of DN (Navarro and Mora, 2005; Dipetrillo et 
al., 2003). Moreover, multivariate analysis showed a 
significant and independent relationship between urinary 
TNF- and albuminuria (Navarro and Mora, 2005). In 
addition, our previous study and the studies of other 
groups have shown that TGF-1 is the key cytokine 
responsible for extracellular matrix (ECM) pathobiology 
observed in DN (Wu et al., 2007). Further renal injury 
results in the release of other proinflammatory cytokines 
such as IL-1 (Sánchez-López et al., 2008) and IL-18 
(Shui et al., 2007) by infiltrating inflammatory cells and 
intrinsic mesangial cells, which may be simultaneously 
present in the glomerular environment. The afore-
mentioned factors can activate mesangial cells to 
increase ECM production, and thereby contribute to the 
progression of renal damage (Sánchez-López et al., 
2008). In the present study, HG treatment led to a 
marked increase in the level of TGF-1, TNF-, IL-1, 
and IL-18 in the supernatants of treated HRMCs (Figures 
2A–D). However, PTN abolished this increase in a dose-
dependent manner. In fact, 20 µmol/L of PTN almost 
completely reversed the expression of IL-1 and TNF-. 
 Chemokines belong to  a  family  of  small  and  related  
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proteins that play an important role in the selective 
recruitment of different leukocyte populations to the sites 
of inflammation. Human renal glomerular mesangial cells 
are potent producers of several chemokines (Schwarz et 
al., 1997). We examined the inhibitory effect of PTN on 
HG-induced mesangial cell chemokine expression, with 
focus on MCP-1, RANTES, and MIP-1a. As shown in 
Figures 2E–G, 50 µmol/L of PTN markedly reduced 
MCP-1, MIP-1a, and RANTES production by approximately 
56, 69, and 79%, respectively (Figures 2G–I). Similar 
inhibitory effect was observed in the case of other 
inflammatory cytokines (Figures 2A–D). Furthermore, we 
examined biopsy specimens from 11 patients with DN; 
MCP-1 and RANTES expressions were strongly 
upregulated in all the specimens (Mezzano et al., 2004). 
Hence, it appears that PTN can block a common pathway 
involved in the production of inflammatory cytokines and 
chemokines. 
The GFR is elevated in the early phase of some types 
of nephropathies like DN. In this respect, vasodilatory 
prostaglandins, including PGE2, have been implicated in 
the glomerular hyperfiltration observed in diabetic 
patients (Viberti et al., 1989) and in experimental models 
of diabetes (DeRubertis and Craven, 1993). In this study, 
we re-evaluated the inhibitory effect of PTN on PGE2 
production in HG-treated HRMCs. The results indicated 
that PTN suppressed HG-induced PGE2 production in a 
dose-dependent manner (Figure 2F). At the same time, 
we also found that PTN strongly reduced HG-induced NO 





glomerular function, and excessive NO production has 
been linked to several forms of glomerular injury (Yu et 
al., 2003). 
In conclusion, our study supports the view that inflam-
matory cytokine and chemokine production is upregulated 
in human renal mesangial cells in a hyperglycemic 
environment. Further, PTN treatment showed a significant 
anti-inflammatory effect on HRMCs in a hyperglycemic 
environment. Although, the mechanism of anti-inflammatory 
effect requires further investigation, the anti-inflammatory 
properties of PTN and its beneficial effects on DN can be 
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